Other languages Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
14.05 ^USD	-2.02%		+4.07%	-6.89%

May. 07	Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 13	Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13
Entrada Therapeutics Adds President Role to COO Nathan Dowden	Jan. 03
Sector Update: Health Care Stocks Gain Pre-Bell Wednesday	Jan. 03
Entrada Therapeutics Promotes Nathan J. Dowden to President	Jan. 03
Entrada Therapeutics, Inc. Announces Board Changes	Dec. 06
US Equity Markets Close Higher Wednesday Following Consumer Sentiment Data	Nov. 22
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 22
Top Midday Decliners	Nov. 22
Sector Update: Health Care Stocks Higher in Afternoon Trading	Nov. 22
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	Nov. 22
Entrada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Entrada Therapeutics, Inc. Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-09-21
Entrada Therapeutics, Inc. Appoints Gina Chapman to its Board of Directors, Effective September 1, 2023	23-08-10
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Entrada Therapeutics Gets UK Nod To Initiate Duchenne Muscular Dystrophy Trial	23-08-01
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of Entr-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	23-08-01
Insider Sell: Entrada Therapeutics	23-07-12
Insider Sell: Entrada Therapeutics	23-07-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Other languages

Filters